PBM
ALDX icon

Propel Bio Management’s Aldeyra Therapeutics ALDX Stock Holding History

Propel Bio Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-730,606
Closed -$1.23M – 30
2026
Q1 		$1.23M Buy
+730,606
New +$3.2M 0.78% 35

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Propel Bio Management's ALDX Position: Q2 2026 in Review

Propel Bio Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 730,606 shares — an estimated $1.23M sold.

Propel Bio Management first reported a position in ALDX in Q1 2026 and held it in 1 quarter. The position peaked at $1.23M in Q1 2026. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Propel Bio Management reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Propel Bio Management sold 730,606 Aldeyra Therapeutics shares in Q2 2026, an estimated $1.23M.
  • Propel Bio Management first reported a position in Aldeyra Therapeutics in Q1 2026 and held it in 1 quarter.
  • Propel Bio Management's Aldeyra Therapeutics position peaked at $1.23M in Q1 2026.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.